---
title: "吉利德科學為其最大創收產品取得了 ‘穩固的勝利’，股價隨之上漲"
description: "吉利德科學的股票在週一上漲，此前這家生物技術巨頭表示已與三家仿製藥製造商達成協議，以推遲它們的 Biktarvy 仿製藥的上市"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/260073982.md"
published_at: "2025-10-06T15:38:10.000Z"
---

# 吉利德科學為其最大創收產品取得了 ‘穩固的勝利’，股價隨之上漲

> 吉利德科學的股票在週一上漲，此前這家生物技術巨頭表示已與三家仿製藥製造商達成協議，以推遲它們的 Biktarvy 仿製藥的上市

Gilead stock popped Monday after the biotech giant said it signed deals with three generic drugmakers to delay their Biktarvy copycats.

### Related Stocks

- [GILD.US - 吉利德科學](https://longbridge.com/zh-HK/quote/GILD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Gilead Sciences (NASDAQ:GILD) Updates FY 2026 Earnings Guidance | Gilead Sciences (NASDAQ:GILD) has updated its FY 2026 earnings guidance, projecting EPS between 8.450-8.850, slightly be | [Link](https://longbridge.com/zh-HK/news/275527709.md) |
| Gilead Sciences (NASDAQ:GILD) Price Target Raised to $135.00 at Argus | Argus has raised its price target for Gilead Sciences (NASDAQ:GILD) from $130.00 to $135.00, maintaining a "buy" rating. | [Link](https://longbridge.com/zh-HK/news/264460688.md) |
| 08:15 ETRoviSys Advances Regulated Industry Facilities Strategy, Names Chris Kulbago Director | RoviSys has promoted Chris Kulbago to Director of Building Technologies, focusing on pharmaceutical, biotech, and food a | [Link](https://longbridge.com/zh-HK/news/276232217.md) |
| NRx Pharmaceuticals Establishes $20 Million ATM Stock Program | NRx Pharmaceuticals has established a $20 million at-the-market stock program, filing a prospectus supplement under an e | [Link](https://longbridge.com/zh-HK/news/276160986.md) |
| Zoetis challenged to return to growth | Zoetis experienced a modest revenue growth of 2% in 2025, the lowest in a decade, primarily due to a 14% decline in its  | [Link](https://longbridge.com/zh-HK/news/276048923.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。